2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
02:00 p.m. - 03:30 p.m.
MCCNO - Hall C
Treatment Considerations, Combination Therapy, Biological Processes, Apoptosis, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Research, AML, Translational Research, Clinical Research, Real-World Evidence, Study Population, Human, Animal Model
PAPER

225 Not all AML-MR are alike: AML-MR defined only by myelodysplasia-related gene mutations is a prognostically distinct entity - a real-world analysis from the german SAL group

Julia M. Unglaub, MD, Sebastian Wolf, MD2, Lydia Kretschmer, MD3, Leo Ruhnke, MD4, Sven Zukunft5, Christoph Schliemann, MD6, Jan-Henrik Mikesch, MD7, Stefan Krause8, Mathias Hänel, MD9, Sabrina Kraus, MD10, Thomas Schroeder, MD11, Martina Crysandt, MD12, Stefan A. Klein, MD13, Dirk Niemann, MD14, Andreas Hochhaus, MD15, Karsten Spiekermann, MD16, Martin Bornhäuser, MD17, Claudia D Baldus, MD18, Hubert Serve, MD19, Carsten Müller-Tidow20, Christoph Röllig, MD21, Björn Steffen22, Tim Sauer, MD23
1 University Hospital Heidelberg, Heidelberg, Germany
2 University Hospital Frankfurt am Main, Frankfurt, Germany
3 University Hospital Dresden, Dresden, Germany
4 University Hospital Dresden, Dresden, Germany
5 University Hospital Dresden, Dresden, Germany
6 University Hospital Muenster, Muenster, Germany
7 University Hospital Muenster, Muenster, Germany
8 University Hospital Erlangen, Erlangen, Germany
9 Clinic Chemnitz, Chemnitz, Germany
10 University Hospital Wuerzburg, Wuerzburg, Germany
11 West German Cancer Center, University Hospital of Essen, Essen, Germany
12 University Hospital Rheinisch-Westfälische Technische Hochschule Aachen University, Aachen, Germany
13 University Hospital Mannheim, Mannheim, Germany
14 Gemeinschaftsklinikum Mittelrhein, Koblenz, Germany
15 Jena University Hospital, Jena, Germany
16 LMU University Hospital, Munich, Germany
17 University Hospital Dresden, Dresden, Germany
18 University Hospital Schleswig-Holstein, Kiel, Germany
19 University Hospital Frankfurt am Main, Frankfurt, Germany
20 University Hospital Heidelberg, Heidelberg, Germany
21 University Hospital Dresden, Dresden, Germany
22 University Hospital Frankfurt am Main, Frankfurt, Germany
23 University Hospital Heidelberg, Heidelberg, Germany
In the WHO and ICC 2022 classification, Myelodysplasia-related gene mutations (MRG) were introduced as a new defining criterion for myelodysplasia-related AML (AML-MR). This delineates a subset of AML-MR patients that meet AML-MR criteria only by the presence of MRGs (MRG-defined AML-MR) but lack myelodysplasia-related cytogenetic abnormalities and/or a history of antecedent hematological disease (AML-MRC). Additionally, in the 2022 ELN genetic risk classification, in the absence of favorable risk genetics, MRGs are categorized as adverse risk markers. Real-world data on this molecularly defined subgroup, and comparisons of its biologic characteristics and prognosis with the other subgroups within the AML-MR entity, remain limited. We therefore performed a retrospective analysis based on the German Study Alliance Leukemia (SAL) registry to compare MRG-defined AML-MR with AML-MRC.

We retrospectively analyzed 416 adults diagnosed with AML-MR according to the ICC 2022 classification who received intensive induction therapy at 14 German SAL centers between August 2018 and December 2025 and for whom a myeloid NGS panel was available. MRG-defined AML-MR was defined as de novo AML assigned to AML-MR solely by the presence of MRGs, in the absence of MR-defining cytogenetic aberrations or antecedent MDS or MDS/MPN. The comparator group (AML-MRC) qualified through MR-defining cytogenetics and/or antecedent MDS or MDS/MPN, irrespective of MRG status. Endpoints were composite complete remission rate after induction therapy (CRc), overall survival (OS), relapse-free survival (RFS). Multivariable logistic and Cox regression models assessed independent predictors of CRc and OS, respectively.

Of the 416 patients, 235 (56%) had MRG-defined AML-MR and 181 (44%) AML-MRC (qualifying via MR cytogenetics in 38% and antecedent MDS or MDS/MPN with or without MR cytogenetics in 62%). Cohorts were comparably fit (ECOG 0-1 in 93% vs 89%) with similar sex distribution; MRG-defined patients were slightly younger (median 62 vs 64 years, p=0.03). 100% of MRG-defined AML-MR and 96% of AML-MRC patients were categorized as adverse-risk AML according to ELN 2022. MRG-defined AML-MR less frequently harbored TP53 mutations (1.7% vs 17%, p<0.001) and more frequently FLT3-ITD/TKD (20% vs 10%, p=0.011) or chromatin/epigenetic mutations (54% vs 44%, p=0.036), with comparable spliceosome mutation frequency (51% vs 48%). All patients received intensive induction (DA-based in 75% vs 43% of MRG-defined AML-MR and AML-MRC; CPX-351 in 25% vs 57%, respectively). CRc after induction was higher in MRG-defined AML-MR (57% vs 45%, p=0.017), and MRG-defined AML-MR status independently predicted CRc after adjustment for induction therapy, age, sex and ECOG (adjusted OR 1.66, 95% CI 1.08-2.56). Allogeneic HCT rates were similar between cohorts (71% vs 67%, p=0.4), with a trend towards a higher transplantation rate in first complete remission (CR1) in MRG-defined AML-MR patients (46% vs 37%, p=0.081). With a median follow-up of 20.1 months (IQR, 6.4-39.6; range, 0.2-79.6), median OS was significantly longer in MRG-defined AML-MR (62.5 vs 27.8 months; log-rank p<0.01); within AML-MRC, OS was similar for the MR cytogenetic and antecedent-MDS/MDS-MPN subgroups (27.3 vs 28.0 months). Among patients transplanted in CR1, OS from transplant was significantly longer for MRG-defined AML-MR (not reached vs 28.6 months, p=0.007). The survival advantage was independent of the induction regimen and remained significant after adjusting for age, ECOG, TP53, number of MRG mutations and karyotype (adjusted HR 0.58-0.59 across models). Among patients achieving a CRc after induction, RFS was significantly longer in MRG-defined AML-MR (not reached vs 26.1 months; log-rank p=0.0071).

In this real-world analysis from the SAL registry, MRG-only AML-MR differed from AML-MRC in both biology and outcome. Patients with MRG-defined AML-MR were slightly younger and carried a distinct co-mutational profile, with less frequent TP53 and more FLT3 mutations. MRG-defined AML-MR achieved higher CR rates and had significantly longer OS and RFS; these differences persisted after adjustment for relevant covariates. AML-MR defines a unique disease group with a distinct biology and outcome. However, the uniformly adverse risk classification of MRG-defined AML-MR and -MRC patients within this category might need reconsideration, as their distinct biology and better outcomes may warrant reclassification.
Julia M. Unglaub, MD: No relevant conflicts of interest to declare.